Related Experiment Video

Updated: Sep 10, 2025

In Vivo Quantification of Hip Arthrokinematics during Dynamic Weight-bearing Activities using Dual Fluoroscopy
07:43

In Vivo Quantification of Hip Arthrokinematics during Dynamic Weight-bearing Activities using Dual Fluoroscopy

Published on: July 2, 2021

3.1K

Beta-Blocker Use and Risk of Hip Arthroplasty in Osteoarthritis: A Retrospective Electronic Health Record Study

Ping-Hao Chiang1, Yang-Chi Lin2, Jing-Yang Huang3

  • 1Department of Medical Education, Chiayi Chang Gung Memorial Hospital, Chiayi 613016, Taiwan.

Life (Basel, Switzerland)
|August 28, 2025
PubMed

Insights

Beta blocker (BB) use is linked to a higher risk of total hip arthroplasty in patients with hip osteoarthritis. Further research is needed to understand this association and specific BB subtypes.

Area of Science:

  • Orthopedic Surgery
  • Pharmacology
  • Epidemiology

Background:

  • Osteoarthritis of the hip is a common condition requiring surgical intervention.
  • Beta blockers (BBs) are widely prescribed medications with potential cardiovascular and other effects.
  • The relationship between BB use and the risk of total hip arthroplasty (THA) in hip osteoarthritis (OA) patients is not fully understood.

Purpose of the Study:

  • To investigate the association between prior beta blocker (BB) use and the three-year risk of total hip arthroplasty (THA) in patients diagnosed with hip osteoarthritis (OA).
  • To compare the risks of THA across different subtypes of beta-blocking agents.

Main Methods:

  • Utilized the TriNetX database to identify patients with hip OA.
  • Divided patients into cohorts with and without BB usage, defining BB users by prescription and refill history.
  • Employed propensity score matching to control for confounding factors and calculated the three-year risk of THA.

Main Results:

  • The study included 313,430 patients; after matching, 23,096 remained in each cohort (BB users vs. non-users).
  • Beta blocker (BB) use was associated with a significantly higher risk of undergoing THA (HR = 1.494).
  • Among BB subtypes, alpha-BBs demonstrated the highest hazard ratio for THA risk compared to the non-BB cohort (HR = 1.639).

Conclusions:

  • Findings suggest a potential association between beta blocker (BB) use and an increased risk of hip arthroplasty in osteoarthritis (OA) patients.
  • The specific subtype of alpha-BBs may carry a higher risk.
  • Further investigation into the underlying mechanisms is warranted, but immediate changes in clinical practice are not recommended.
Abstract

Keywords:
beta-blockerscohort studynon selective beta-blockersosteoarthritis of the hipselective beta-blockertotal hip arthroplasty

More Related Videos

The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve09:51

The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve

Published on: September 7, 2022

3.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

370

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
863
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
609
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911